Shire plc (NASDAQ:SHPG) jumped 0.13 points or 0.07% on strong buying and was last priced at $177.23 per share. The shares saw huge fund flow intraday; a massive $20.77 million made their way in through the upticks but an even bigger $25.8 million made their way out through downticks. As per the last observation, the net money flow stood at $(-5.03) million and the up/down ratio was found to be 0.81. The shares have seen a weekly value change of -7.76% .A block trade was recorded in the company shares with a net money flow of $(-5.34) million. The composite value of the funds in upticks was $0 million and the total value of funds in downticks was $5.34. As can be seen from the data, the block transaction had the up/down ratio of 0.
Currently the company Insiders own 2% of Shire plc shares according to the proxy statements. Institutional Investors own 28.88% of Shire plc shares.
Shire plc (NASDAQ:SHPG) stock ended Monday session in the red zone in a volatile trading. The stock closed down 3.51 points or 1.98% at $173.59 with 2,256,542 shares getting traded. Post opening the session at $175.15, the shares hit an intraday low of $173.27 and an intraday high of $177.82 and the price was in this range throughout the day. The company has a market cap of $34,263 million and the number of outstanding shares have been calculated to be 197,380,100 shares. The 52-week high of Shire plc (NASDAQ:SHPG) is $270.63 and the 52-week low is $147.6.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Morgan Stanley assumes its ratings on Shire plc (NASDAQ:SHPG). According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on June 3, 2016.
Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).